Implementation of the Lupus Low Disease Activity State in Pediatric Rheumatology Care: The Role of the Visual Analog Scale.
Journal
ACR open rheumatology
ISSN: 2578-5745
Titre abrégé: ACR Open Rheumatol
Pays: United States
ID NLM: 101740025
Informations de publication
Date de publication:
28 Oct 2024
28 Oct 2024
Historique:
revised:
02
08
2024
received:
01
04
2024
accepted:
05
04
2024
medline:
29
10
2024
pubmed:
29
10
2024
entrez:
29
10
2024
Statut:
aheadofprint
Résumé
We compared the measurement properties of a traditional physician global assessment of disease activity (PhGA) 10-cm visual analog scale (PhGA We used a secondary data analysis from a convenience sample of 100 patients with cSLE followed every three months for up to seven visits. Ratings of PhGA In 600 visits, the median (range) scores of PhGA PhGA
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Cincinnati Children's Hospital Medical Center Pediatric Musculoskeletal and Rheumatology Innovation Core Center (PORTICO)
Organisme : CLC NIH HHS
ID : 5P30AR076316
Pays : United States
Organisme : CLC NIH HHS
ID : P30 AR070549
Pays : United States
Organisme : The Cincinnati Rheumatic Disease Core Center
Informations de copyright
© 2024 The Author(s). ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.
Références
Mina R, Brunner HI. Pediatric lupus–are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus? Rheum Dis Clin North Am 2010;36(1):53–80, vii–viii.
Smith EMD, Aggarwal A, Ainsworth J, et al. Towards development of treat to target (T2T) in childhood‐onset systemic lupus erythematosus: PReS‐endorsed overarching principles and points‐to‐consider from an international task force. Ann Rheum Dis 2023;82(6):788–798.
Franklyn K, Lau CS, Navarra SV, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis 2016;75(9):1615–1621.
Smith EMD, Tharmaratnam K, Al‐Abadi E, et al. Attainment of low disease activity and remission targets reduces the risk of severe flare and new damage in childhood lupus. Rheumatology (Oxford) 2022;61(8):3378–3389.
Cody EM, Wilson BE, Ogbu EA, et al. Usefulness of the LLDAS as a treatment target in childhood‐onset SLE. Lupus Sci Med 2023;10(1):e000884.
Smith EMD, Aggarwal A, Ainsworth J, et al. PReS‐endorsed international childhood lupus T2T task force definition of childhood LLDAS (cLLDAS). Clin Immunol 2023;250:109296.
Isenberg DA, Allen E, Farewell V, et al. An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA. Ann Rheum Dis 2011;70(1):54–59.
Brunner HI, Higgins GC, Wiers K, et al. Prospective validation of the provisional criteria for the evaluation of response to therapy in childhood‐onset systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2010;62(3):335–344.
Brunner HI, Holland MJ, Beresford MW, et al; Paediatric Rheumatology International Trial Organisation and Pediatric Rheumatology Collaborative Study Group. American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood‐Onset Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2019;71(5):579–590.
Ruperto N, Ravelli A, Oliveira S, et al; Pediatric Rheumatology International Trials Organization. The Pediatric Rheumatology International Trials Organization/American College of Rheumatology provisional criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: prospective validation of the definition of improvement. Arthritis Rheum. 2006;55(3):355–363.
Petri M, Kim MY, Kalunian KC, et al; OC‐SELENA Trial. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005;353(24):2550–2558.
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40(9):1725.
Gordon C, Sutcliffe N, Skan J, et al. Definition and treatment of lupus flares measured by the BILAG index. Rheumatology (Oxford) 2003;42(11):1372–1379.
Touma Z, Urowitz MB, Gladman DD. SLEDAI‐2K for a 30‐day window. Lupus 2010;19(1):49–51.
Brunner HI, Mina R, Pilkington C, et al. Preliminary criteria for global flares in childhood‐onset systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2011;63(9):1213–223.